Cell Therapy Raw Materials Market Size, Share & Trends Analysis Report By Product (Media, Sera, Antibodies, Reagents & Buffers, Cell Culture Supplements), By End-use, By Region,- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2025-2034

Cell Therapy Raw Materials Market Size and Research

The cell therapy raw materials market size was exhibited at USD 5.52 billion in 2024 and is projected to hit around USD 29.3 billion by 2034, growing at a CAGR of 18.17% during the forecast period 2025 to 2034.

Cell Therapy Raw Materials Market Key Takeaways:

• The cell culture supplements segment held the largest market share of 25.27% in 2024.
• The media segment is expected to grow at the highest CAGR during the forecast period.
• The biopharmaceutical & pharmaceutical companies segment held the largest market share of 54.0% in 2024.
• On the other hand, the CMOs & CROs segment is anticipated to register the fastest CAGR of over the forecast period. 
• North America dominated the cell therapy raw materials industry with a share of 47.30% in 2024.

U.S. Cell Therapy Raw Materials market Size and Growth 2025 to 2034

The U.S. cell therapy raw materials market size is evaluated at USD 2.0 billion in 2024 and is projected to be worth around USD 10.5 billion by 2034, growing at a CAGR of 16.27% from 2025 to 2034.

North America dominated the cell therapy raw materials industry with a share of 47.30% in 2024. This is attributed to the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders which has led to a growing demand for innovative cell-based therapies. These therapies offer promising treatment options that can potentially address the unmet medical needs of patients, spurring the demand for raw materials. Furthermore, the region's robust healthcare infrastructure and well-established regulatory framework have created a conducive environment for the development and commercialization of cell therapies. This has attracted investments from both government agencies and private companies, fueling research and development activities in the field.

U.S. Cell Therapy Raw Materials Market Trends

The U.S. cell therapy raw materials market is experiencing significant growth due to the increasing demand for advanced therapies in areas like cancer treatment, autoimmune diseases, and regenerative medicine.

Europe Cell Therapy Raw Materials Market Trends

Europe's cell therapy raw materials market was identified as a lucrative region in this industry. The rising demand for advanced therapy medicinal products and cell biology research in Europe has shown significant development in the past few years.

The UK cell therapy raw materials market is growing rapidly, driven by the increasing adoption of cell-based therapies for treating diseases such as cancer, autoimmune disorders, and genetic conditions. Advances in regenerative medicine and personalized treatments are fueling demand for high-quality raw materials like growth factors, cytokines, and cell culture media, which are critical for the development and production of cell therapies.

The cell therapy raw materials market in Germany is experiencing significant growth, driven by the increasing demand for innovative therapies in regenerative medicine and cancer treatment.

Asia Pacific Cell Therapy Raw Materials Market Trends

Asia Pacific is anticipated to showcase the fastest CAGR of 18.92% during 2025-2030. The increasing prevalence of chronic diseases and degenerative disorders in the region has spurred the demand for innovative cell therapies. These therapies offer promising solutions for conditions such as cancer, cardiovascular diseases, and neurological disorders, thereby fueling the need for raw materials in their production. Moreover, the supportive regulatory environment in many Asia Pacific countries including China, India has also been instrumental in fostering the growth of the cell therapy raw materials market.

China’s cell therapy raw materials market is rapidly expanding, fueled by the country’s growing investment in biotechnology and healthcare innovation. As the demand for advanced treatments, such as gene therapies, stem cell applications, and cancer immunotherapies, increases, there is a corresponding need for high-quality raw materials like culture media, growth factors, and reagents.

Japan’s cell therapy raw materials market is experiencing significant growth, driven by the country’s strong focus on medical innovation and regenerative medicine. As the demand for advanced therapies in areas like cancer treatment, stem cell therapies, and tissue regeneration increases, there is a rising need for high-quality raw materials, including culture media, growth factors, and scaffolds.

Middle East & Africa Cell Therapy Raw Materials Market Trends

The MEA Cell Therapy Raw Materials Market is driven by the rising demand for advanced therapies, leading to the increasing adoption of cell and gene therapies. These therapies have the potential of treating chronic diseases, including cancer, autoimmune diseases, and rare genetic disorders. Moreover, biopharma companies and CDMOs in the region are establishing facilities for cell therapy research, driving the need for high-quality raw materials like growth factors, cytokines, and culture media.

The cell therapy raw materials market in South Africa is expanding, driven by growing demand for advanced treatments in oncology and regenerative medicine. Kuwait's Cell Therapy Raw Materials Market is anticipated to grow moderately over the forecast period.

The cell therapy raw materials market in the UAE is experiencing strong growth, fueled by advancements in regenerative medicine and personalized treatments.

Report Scope of Cell Therapy Raw Materials Market

Cell Therapy Raw Materials Market By Product Insights

Based on product, the market is segmented into media, sera, cell culture supplements, antibodies, reagents & buffers, and others. The cell culture supplements segment held the largest market share of 25.27% in 2024. Due to the rising demand for animal-free cell-based therapies, the segment is anticipated to grow during the forecast period. Numerous market participants are actively exploring untapped opportunities in the market through initiatives such as the development of new products & business expansion.

The media segment is expected to grow at the highest CAGR during the forecast period. This is attributed to advancements in cell therapy research and development that have driven the need for specialized media products that support the growth and expansion of therapeutic cells. Moreover, the increasing product development of media for stem cell-based therapy would likely drive segment growth over the coming years. For instance, in May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium, a chemically defined medium that improves CAR T-cell production with better consistency, process control, and faster regulatory approval

Cell Therapy Raw Materials Market By End Use Insights

Based on the end use, the market is segmented into biopharmaceutical & pharmaceutical companies, CMOs & CROs, and others. The biopharmaceutical & pharmaceutical companies segment held the largest market share of 54.0% in 2024. These sectors have increasingly recognized the immense potential of cell therapy in revolutionizing healthcare by providing novel treatments for a wide range of diseases, including cancer, autoimmune disorders, and degenerative conditions.

As a result, they have significantly ramped up their investments in research, development, and commercialization of cell-based therapies, spurring the demand for high-quality raw materials essential for cell therapy production. For instance, in September 2023, Novo Nordisk A/S announced an investment of USD 136 million for the construction of a cell therapy manufacturing facility at Cellerator in Denmark. The manufacturing facility, which will be housed at the Technical University of Denmark (DTU), will produce cell therapies, particularly stem cell therapies, for use in preliminary clinical studies.

On the other hand, the CMOs & CROs segment is anticipated to register the fastest CAGR of over the forecast period. The escalating trend of outsourcing services to CROs and CMOs has significantly propelled the growth of this end User segment in the market. As the field of cell therapy continues to advance and gain prominence in the healthcare industry, biopharmaceutical companies are increasingly seeking specialized expertise and resources to streamline their production processes.

CROs and CMOs offer a comprehensive range of services, from research and development to manufacturing, allowing these companies to focus on their core competencies while minimizing operational costs and risks. This strategic shift towards outsourcing has created a surge in demand for raw materials essential for cell therapy production, including growth factors, culture media, among others by CMOs, & CROs, thereby fostering the expansion of the market. Moreover, as the biopharmaceutical industry continues to invest in cell therapy research and development, the demand for raw materials will persistently rise, benefiting both CMOs and CROs as key contributors to advancements in this promising field.

Some of the prominent players in the cell therapy raw materials market include:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher
• Sartorius Stedim Biotech
• Actylis.
• ACROBiosystems
• STEMCELL Technologies.
• Grifols, S.A.
• Charles River Laboratories
• RoosterBio, Inc.
• PromoCell GmbH

Cell Therapy Raw Materials Market Recent Development

• In December 2024, BioCentriq signed a long-term lease for a new manufacturing facility in Princeton, NJ, which will serve as its headquarters. The USD 12M investment will enhance its capabilities in cell therapy development and production
  
  
• In October 2024, Thermo Fisher Scientific established a bioprocess design center in Genome Valley, Hyderabad. This move reflects the growing demand in the market.
  
  
• In June 2023, StemCyte signed a collaboration agreement with a state-of-the-art US immune cell therapy business, to provide raw materials for drug preparation in allogeneic modified cell therapy.
  
  
• In June 2023, FUJIFILM Corporation launched human iPSC-derived iCell Blood-Brain Barrier Isogenic Kit. The kit replicates the human barrier between the blood and the brain and can help with drug discovery, medication development, and the study of diseases of the central nervous system.
  
  
• In June 2022, OrganaBio opened a new manufacturing facility for good manufacturing practices. The facility serves as the central hub for manufacturing extensive portfolio of perinatal and adult blood-derived tissue and cells, reinforcing the company's dedication to delivering high-quality solutions for the cell therapy industry.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the cell therapy raw materials market

By Product Scope

• Media
• Sera
• Cell Culture Supplements
• Antibodies
• Reagents & Buffers
• Others

By End Use Scope

• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Others

By Regional

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)